Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Internal Medicine Neurology Oncology Pediatrics Respiratory Medicine Surgery
Congress Coverage
2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting

Keynote Webinar | Spotlight on Diet and Diabetes

Watch on-demand

An expert-led symposium exploring the prevention and management of type 2 diabetes through dietary interventions. 
ADVANCED SEARCH
Log in
Top
Current Hypertension Reports

20-11-2023 | Hypertension | Hypertension and the Kidney (RM Carey, Section Editor)

Underlying Mechanisms and Treatment of Hypertension in Glomerular Diseases

Authors: Sahar H. Koubar, Alejandro Garcia-Rivera, Muner M. B. Mohamed, John E. Hall, Michael E. Hall, Mohamed Hassanein

Published in: Current Hypertension Reports

Login to get access

Abstract

Purpose of Review

This review aims to explore the underlying mechanisms that lead to hypertension in glomerular diseases and the advancements in treatment strategies and to provide clinicians with valuable insights into the pathophysiological mechanisms and evidence-based therapeutic approaches for managing hypertension in patients with glomerular diseases.

Recent Findings

In recent years, there have been remarkable advancements in our understanding of the immune and non-immune mechanisms that are involved in the pathogenesis of hypertension in glomerular diseases. Furthermore, this review will encompass the latest data on management strategies, including RAAS inhibition, endothelin receptor blockers, SGLT2 inhibitors, and immune-based therapies.

Summary

Hypertension (HTN) and cardiovascular diseases are leading causes of mortality in glomerular diseases. The latter are intricately related with hypertension and share common pathophysiological mechanisms. Hypertension in glomerular disease represents a complex and multifaceted interplay between kidney dysfunction, immune-mediated, and non-immune-mediated pathology. Understanding the complex mechanisms involved in this relationship has evolved significantly over the years, shedding light on the pathophysiological processes underlying the development and progression of glomerular disease-associated HTN, and is crucial for developing effective therapeutic strategies and improving patients’ outcomes.
Literature
1.
Quirós PL, Ceballos M, Remón C, Hernández Romero MC, Benavides B, Pérez Pérez-Ruilópez MA, Lozano A, Aznar E, Rivero M, Fernández Ruiz E. Systemic arterial hypertension in primary chronic glomerulonephritis: prevalence and its influence on the renal prognosis. Nefrologia. 2005;25:250–7. PubMed
2.
Oh TR, Choi HS, Oh SW, Oh J, Lee DW, Kim CS, Ma SK, Kim SW, Bae EH, Korean GlomeruloNEphritis sTudy (KoGNET) Group. Association between the progression of immunoglobulin A nephropathy and a controlled status of hypertension in the first year after diagnosis. Korean J Intern Med. 2022;37:146–53. CrossRef
3.
4.
Mebrahtu TF, Morgan AW, West RM, Stewart PM, Pujades-Rodriguez M. Oral glucocorticoids and incidence of hypertension in people with chronic inflammatory diseases: a population-based cohort study. CMAJ. 2020;192:E295–301. PubMedPubMedCentralCrossRef
5.
Mejia-Vilet JM, López-Hernández YJ, Trujeque-Matos M, Santander-Velez JI, Cano-Verduzco ML, Cruz C, Morales-Buenrostro LE. High frequency of nocturnal hypertension in lupus nephritis: should ABPM be implemented in usual practice? Clin Rheumatol. 2020;39:1147–55. PubMedCrossRef
6.
7.
Sethna CB, Meyers KEC, Mariani LH, Psoter KJ, Gadegbeku CA, Gibson KL, Srivastava T, Kretzler M, Brady TM. Blood pressure and visit-to-visit blood pressure variability among individuals with primary proteinuric glomerulopathies. Hypertens (Dallas, Tex 1979). 2017;70:315–323.
8.
Stefanski A, Schmidt KG, Waldherr R, Ritz E. Early increase in blood pressure and diastolic left ventricular malfunction in patients with glomerulonephritis. Kidney Int. 1996;50:1321–6. PubMedCrossRef
9.
Feiner HD, Cabili S, Baldwin DS, Schacht RG, Gallo GR. Intrarenal vascular sclerosis in IgA nephropathy. Clin Nephrol. 1982;18:183–92. PubMed
10.
Küster S, Mehls O, Seidel C, Ritz E. Blood pressure in minimal change and other types of nephrotic syndrome. Am J Nephrol. 1990;10(Suppl 1):76–80. PubMed
11.
Shaharir SS, Mustafar R, Mohd R, Mohd Said MS, Gafor HA. Persistent hypertension in lupus nephritis and the associated risk factors. Clin Rheumatol. 2015;34:93–7. PubMedCrossRef
12.
13.
Olsen F. Inflammatory cellular reaction in hypertensive vascular disease in man. Acta Pathol Microbiol Scand A. 1972;80:253–6. PubMed
14.
Trott DW, Thabet SR, Kirabo A, et al. Oligoclonal CD8+ T cells play a critical role in the development of hypertension. Hypertens (Dallas, Tex 1979). 2014;64:1108–15.
15.
Liu Y, Rafferty TM, Rhee SW, Webber JS, Song L, Ko B, Hoover RS, He B, Mu S. CD8+ T cells stimulate Na-Cl co-transporter NCC in distal convoluted tubules leading to salt-sensitive hypertension. Nat Commun. 2017;8:14037. PubMedPubMedCentralCrossRef
16.
• Linke A, Tiegs G, Neumann K. Pathogenic T-cell responses in immune-mediated glomerulonephritis. Cells. 2022;11:1625. This paper summarizes the mechanisms of pathogenic T-cell responses leading to glomerular damage and renal inflammation in Glomerulonephritis. PubMedPubMedCentralCrossRef
17.
Chan CT, Sobey CG, Lieu M, et al. Obligatory role for B cells in the development of angiotensin II–dependent hypertension. Hypertension. 2015;66:1023–33. PubMedCrossRef
18.
19.
Norlander AE, Saleh MA, Kamat N V, et al. Interleukin-17A regulates renal sodium transporters and renal injury in angiotensin II-induced hypertension. Hypertens (Dallas, Tex 1979). 2016;68:167–74.
20.
Kassan M, Galan M, Partyka M, Trebak M, Matrougui K. Interleukin-10 released by CD4(+)CD25(+) natural regulatory T cells improves microvascular endothelial function through inhibition of NADPH oxidase activity in hypertensive mice. Arterioscler Thromb Vasc Biol. 2011;31:2534–42. PubMedPubMedCentralCrossRef
21.
Chen X-H, Ruan C-C, Ge Q, Ma Y, Xu J-Z, Zhang Z-B, Lin J-R, Chen D-R, Zhu D-L, Gao P-J. Deficiency of complement C3a and C5a receptors prevents angiotensin II-induced hypertension via regulatory T cells. Circ Res. 2018;122:970–83. PubMedCrossRef
22.
Hoxha E, Harendza S, Pinnschmidt H, Panzer U, Stahl RAK. M-type phospholipase A2 receptor autoantibodies and renal function in patients with primary membranous nephropathy. Clin J Am Soc Nephrol. 2014;9:1883–90. PubMedPubMedCentralCrossRef
23.
24.
Drummond GR, Vinh A, Guzik TJ, Sobey CG. Immune mechanisms of hypertension. Nat Rev Immunol. 2019;19:517–32. PubMedCrossRef
25.
Scheen M, Adedjouma A, Esteve E, et al. Kidney disease in antiphospholipid antibody syndrome: risk factors, pathophysiology and management. Autoimmun Rev. 2022;21:103072. PubMedCrossRef
26.
Gadau J, Peters H, Kastner C, Kühn H, Nieminen-Kelhä M, Khadzhynov D, Krämer S, Castrop H, Bachmann S, Theilig F. Mechanisms of tubular volume retention in immune-mediated glomerulonephritis. Kidney Int. 2009;75:699–710. PubMedCrossRef
27.
Wenzel U, Turner JE, Krebs C, Kurts C, Harrison DG, Ehmke H. Immune Mechanisms in Arterial Hypertension. J Am Soc Nephrol. 2016;27:677–86. PubMedCrossRef
28.
29.
Vinh A, Chen W, Blinder Y, Weiss D, Taylor WR, Goronzy JJ, Weyand CM, Harrison DG, Guzik TJ. Inhibition and genetic ablation of the B7/CD28 T-cell costimulation axis prevents experimental hypertension. Circulation. 2010;122:2529–37. PubMedPubMedCentralCrossRef
30.
Heymann F, Meyer-Schwesinger C, Hamilton-Williams EE, Hammerich L, Panzer U, Kaden S, Quaggin SE, Floege J, Gröne H-J, Kurts C. Kidney dendritic cell activation is required for progression of renal disease in a mouse model of glomerular injury. J Clin Invest. 2009;119:1286–97. PubMedPubMedCentralCrossRef
31.
Hochheiser K, Tittel A, Kurts C. Kidney dendritic cells in acute and chronic renal disease. Int J Exp Pathol. 2011;92:193–201. PubMedCentralCrossRef
32.
33.
Krishnan SM, Sobey CG, Latz E, Mansell A, Drummond GR. IL-1β and IL-18: inflammatory markers or mediators of hypertension? Br J Pharmacol. 2014;171:5589–602. PubMedPubMedCentralCrossRef
34.
Wenzel UO, Kemper C, Bode M. The role of complement in arterial hypertension and hypertensive end organ damage. Br J Pharmacol. 2021;178:2849–62. PubMedCrossRef
35.
Bao X, Meng G, Zhang Q, et al. Elevated serum complement C3 levels are associated with prehypertension in an adult population. Clin Exp Hypertens. 2017;39:42–9. PubMedCrossRef
36.
Lehrke I, Waldherr R, Ritz E, Wagner J. Renal endothelin-1 and endothelin receptor type B expression in glomerular diseases with proteinuria. J Am Soc Nephrol. 2001;12:2321–9. PubMedCrossRef
37.
Benz K, Amann K. Thrombotic microangiopathy: new insights. Curr Opin Nephrol Hypertens. 2010;19:242–7. PubMedCrossRef
38.
Shibagaki Y, FUJITA T. Thrombotic microangiopathy in malignant hypertension and hemolytic uremic syndrome (HUS)/thrombotic thrombocytopenic purpura (TTP): can we differentiate one from the other? Hypertens Res. 2005;28:89–95. PubMedCrossRef
39.
Feuer DS, Handberg EM, Mehrad B, Wei J, Bairey Merz CN, Pepine CJ, Keeley EC. Microvascular dysfunction as a systemic disease: a review of the evidence. Am J Med. 2022;135:1059–68. PubMedPubMedCentralCrossRef
40.
Kanzaki G, Tsuboi N, Haruhara K, Koike K, Ogura M, Shimizu A, Yokoo T. Factors associated with a vicious cycle involving a low nephron number, hypertension and chronic kidney disease. Hypertens Res. 2015;38:633–41. PubMedCrossRef
41.
42.
Bidani AK, Griffin KA. Pathophysiology of hypertensive renal damage. Hypertension. 2004;44:595–601. PubMedCrossRef
43.
Ray EC, Rondon-Berrios H, Boyd CR, Kleyman TR. Sodium retention and volume expansion in nephrotic syndrome: implications for hypertension. Adv Chronic Kidney Dis. 2015;22:179–84. PubMedPubMedCentralCrossRef
44.
45.
Nishiyama A, Konishi Y, Ohashi N, et al. Urinary angiotensinogen reflects the activity of intrarenal renin-angiotensin system in patients with IgA nephropathy. Nephrol Dial Transplant. 2011;26:170–7. PubMedCrossRef
46.
Sørensen SS, Amdisen A, Pedersen EB. Abnormal proximal tubular sodium handling in normotensive patients with chronic glomerulonephritis and normal glomerular filtration rate. Scand J Clin Lab Invest. 1987;47:785–91. PubMedCrossRef
47.
Konishi Y, Okada N, Okamura M, Morikawa T, Okumura M, Yoshioka K, Imanishi M. Sodium sensitivity of blood pressure appearing before hypertension and related to histological damage in immunoglobulin a nephropathy. Hypertension. 2001;38:81–85.
48.
Lovell AR, Ernst ME. Drug-induced hypertension: focus on mechanisms and management. Curr Hypertens Rep. 2017;19:39. PubMedCrossRef
49.
Kim SM, Chin HJ, Oh YK, Kim YS, Kim S, Lim CS. Blood pressure-related genes and the progression of IgA nephropathy. Nephron Clin Pract. 2009;113:c301–8. PubMedCrossRef
50.
Shinzawa M, Yamamoto R, Nagasawa Y, et al. Gene polymorphisms contributing to hypertension in immunoglobulin A nephropathy. Clin Exp Nephrol. 2012;16:250–8. PubMedCrossRef
51.
Nadkarni GN, Coca SG. APOL1 and blood pressure changes in young adults. Kidney Int. 2017;92:793–5. PubMedCrossRef
52.
Kim H, Lefebvre F, Hoa S, Hudson M. Mortality and morbidity in scleroderma renal crisis: a systematic literature review. J scleroderma Relat Disord. 2021;6:21–36. PubMedCrossRef
53.
54.
Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100:S1–276. CrossRef
55.
Herrera J, Ferrebuz A, MacGregor EG, Rodriguez-Iturbe B. Mycophenolate mofetil treatment improves hypertension in patients with psoriasis and rheumatoid arthritis. J Am Soc Nephrol. 2006;17:S218–25. PubMedCrossRef
56.
57.
Wolf VL, Taylor EB, Ryan MJ. Cyclophosphamide treatment for hypertension and renal injury in an experimental model of systemic lupus erythematosus. Physiol Rep. 2019;7:e14059. PubMedPubMedCentralCrossRef
58.
Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int. 2021;99:S1–87. CrossRef
59.
Neale EP, Do RV, Probst Y, Beck E, Tran TB, Lambert K. Lifestyle interventions, kidney disease progression, and quality of life: a systematic review and meta-analysis. Kidney Med. 2023;5:100643. PubMedPubMedCentralCrossRef
60.
Xie X, Liu Y, Perkovic V, et al. Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: a Bayesian network meta-analysis of randomized clinical trials. Am J Kidney Dis. 2016;67:728–41. PubMedCrossRef
61.
Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet (London, England). 1997;349:1857–63.
62.
Ruggenenti P, Perna A, Gherardi G, Gaspari F, Benini R, Remuzzi G. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy. Lancet (London, England). 1998;352:1252–6. PubMedCrossRef
63.
Maschio G, Alberti D, Locatelli F, Mann JF, Motolese M, Ponticelli C, Ritz E, Janin G, Zucchelli P. Angiotensin-converting enzyme inhibitors and kidney protection: the AIPRI trial. The ACE Inhibition in Progressive Renal Insufficiency (AIPRI) Study Group. J Cardiovasc Pharmacol. 1999;33 Suppl 1:S16–20;discussion S41–3.
64.
Raghunathan V, Sethi SK, Dragon-Durey MA, Dhaliwal M, Raina R, Jha P, Bansal SB, Kher V. Targeting renin-angiotensin system in malignant hypertension in atypical hemolytic uremic syndrome. Indian J Nephrol. 2017;27:136–40. PubMedPubMedCentralCrossRef
65.
Plasse RA, Nee R, Olson SW. Aliskiren as an adjunct therapy for atypical hemolytic uremic syndrome. Clin Kidney J. 2020;13:39–41. PubMedCrossRef
66.
Chen F-Y, Chen C-H, Lin C-C. Hypertensive crisis and refractory hypertension caused by atypical hemolytic uremic syndrome and effect of eculizumab. Acta Cardiol Sin. 2018;34:446–9. PubMedPubMedCentral
67.
• Heerspink HJL, Radhakrishnan J, Alpers CE, et al. Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial. Lancet (London, England). 2023;401:1584–94. This paper shows that treatment with sparsentan produced meaningful reduction in proteinuria and blood pressure in adults with IgA nephropathy. PubMedCrossRef
68.
Zhou Y, Chi J, Huang Y, Dong B, Lv W, Wang YG. Efficacy and safety of endothelin receptor antagonists in type 2 diabetic kidney disease: a systematic review and meta-analysis of randomized controlled trials. Diabet Med. 2021;38:e14411. PubMedCrossRef
69.
Wheeler DC, Jongs N, Stefansson BV, et al. Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial. Nephrol Dial Transplant. 2022;37:1647–56. PubMedCrossRef
70.
Wheeler DC, Toto RD, Stefánsson BV, et al. A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Kidney Int. 2021;100:215–24. PubMedCrossRef
71.
•• Agarwal R, Ruilope LM, Ruiz-Hurtado G, et al. Effect of finerenone on ambulatory blood pressure in chronic kidney disease in type 2 diabetes. J Hypertens. 2023;41:295–302. Findings in this study show a significant blood pressure reduction with finerenone in patients with CKD and type 2 diabetes. This may be the case in other GD (ongoing clinical trials). PubMedCrossRef
72.
Canney M, Gunning HM, Zheng Y, Rose C, Jauhal A, Hur SA, Sahota A, Reich HN, Barbour SJ. The risk of cardiovascular events in individuals with primary glomerular diseases. Am J Kidney Dis. 2022;80:740–50. PubMedCrossRef
73.
Oh TR, Choi HS, Oh SW, Oh J, Lee DW, Kim CS, Ma SK, Kim SW, Bae EH. Association between the progression of immunoglobulin A nephropathy and a controlled status of hypertension in the first year after diagnosis. Korean J Intern Med. 2022;37:146–53. PubMedCrossRef
74.
Berthoux F, Mohey H, Laurent B, Mariat C, Afiani A, Thibaudin L. Predicting the risk for dialysis or death in IgA nephropathy. J Am Soc Nephrol. 2011;22:752–61. PubMedPubMedCentralCrossRef
75.
Le W, Liang S, Hu Y, Deng K, Bao H, Zeng C, Liu Z. Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population. Nephrol Dial Transplant. 2012;27:1479–85. PubMedCrossRef
76.
77.
Han X, Xiao Y, Tang Y, Zheng X, Anwar M, Qin W. Clinical and pathological features of immunoglobulin A nephropathy patients with nephrotic syndrome. Clin Exp Med. 2019;19:479–86. PubMedCrossRef
78.
Zhang W, Zhou Q, Hong L, Chen W, Yang S, Yang Q, Chen W, Yu X. Clinical outcomes of IgA nephropathy patients with different proportions of crescents. Medicine (Baltimore). 2017;96:e6190. PubMedCrossRef
79.
Selewski DT, Ambruzs JM, Appel GB, et al. Clinical characteristics and treatment patterns of children and adults with IgA nephropathy or IgA vasculitis: findings from the CureGN study. Kidney Int Reports. 2018;3:1373–84. CrossRef
80.
Subías R, Botey A, Darnell A, Montoliu J, Revert L. Malignant or accelerated hypertension in IgA nephropathy. Clin Nephrol. 1987;27:1–7. PubMed
81.
Sevillano ÁM, Cabrera J, Gutiérrez E, Morales E, Mérida E, Huerta A, Cavero T, Hernández E, Moreno JA, Praga M. Malignant hypertension: a type of IgA nephropathy manifestation with poor prognosis. Nefrologia. 2015;35:42–9. PubMed
82.
Zheng Y, Wang Y, Liu S, Wu J, Duan S, Zhu H, Wu D, Cai G, Chen X. Potential blood pressure goals in IgA nephropathy: prevalence, awareness, and treatment rates in chronic kidney disease among patients with hypertension in China (PATRIOTIC) Study. Kidney Blood Press Res. 2018;43:1786–95. PubMedCrossRef
83.
Keskar V, Jamale TE, Kulkarni MJ, Kiggal Jagadish P, Fernandes G, Hase N. Minimal-change disease in adolescents and adults: epidemiology and therapeutic response. Clin Kidney J. 2013;6:469–72. PubMedPubMedCentralCrossRef
84.
Waldman M, Crew RJ, Valeri A, Busch J, Stokes B, Markowitz G, D’Agati V, Appel G. Adult minimal-change disease. Clin J Am Soc Nephrol. 2007;2:445–53. PubMedCrossRef
85.
Gellineo L, Bulimbašić S, Ćorić M, et al. Hypertension in primary glomerulonephritis - report from the Croatian Referral Centre for Glomerular Diseases. J Hypertens. 2018;36:e274. CrossRef
86.
Shiiki H, Saito T, Nishitani Y, et al. Prognosis and risk factors for idiopathic membranous nephropathy with nephrotic syndrome in Japan. Kidney Int. 2004;65:1400–7. PubMedCrossRef
87.
Paulo RPMB, Jorge LB, Yu L, Woronik V, Dias CB. Diagnosis and course of membranous nephropathy in adults: comparison by age group. Kidney Blood Press Res. 2022;47:693–701. PubMedCrossRef
88.
89.
Dumoulin A, Hill GS, Montseny J-J, Meyrier A. Clinical and morphological prognostic factors in membranous nephropathy: significance of focal segmental glomerulosclerosis. Am J Kidney Dis. 2003;41:38–48. PubMedCrossRef
90.
Forster BM, Nee R, Little DJ, Greasley PJ, Hughes JB, Gordon SM, Olson SW. Focal segmental glomerulosclerosis, risk factors for end stage kidney disease, and response to immunosuppression. Kidney360. 2021;2:105–113.
91.
92.
Polanco NA, Soto-Abraham M, Vázquez Rangel A. Clinical and pathological characteristics of pauci-immune renal vasculitis in Mexico: report of 23 cases. Rev Colomb Reumatol (English Ed). 2017;24:70–78.
93.
Weiner M, Goh SM, Mohammad AJ, et al. Outcome and treatment of elderly patients with ANCA-associated vasculitis. Clin J Am Soc Nephrol. 2015;10:1128–35. PubMedPubMedCentralCrossRef
94.
Chen Y-X, Zhang W, Chen X-N, Ni L-Y, Shen P-Y, Wang W-M, Chen N. Clinical analysis of ANCA-associated renal vasculitis patients with chronic dialysis. Clin Exp Rheumatol. 2014;32:S5-10. PubMed
95.
Moroni G, Binda V, Leoni A, Raffiotta F, Quaglini S, Banfi G, Messa P. Predictors of renal survival in ANCA-associated vasculitis. Validation of a histopatological classification schema and review of the literature. Clin Exp Rheumatol. 2015;33:S–56–63.
96.
Kaplan-Pavlovcic S, Cerk K, Kveder R, Lindic J, Vizjak A. Clinical prognostic factors of renal outcome in anti-neutrophil cytoplasmic autoantibody (ANCA)-associated glomerulonephritis in elderly patients. Nephrol Dial Transplant. 2003;18(Suppl 5):v5-7. PubMedCrossRef
97.
Saleh M, Eltoraby EE, Tharwat S, Nassar MK. Clinical and histopathological features and short-term outcomes of lupus nephritis: a prospective study of 100 Egyptian patients. Lupus. 2020;29:993–1001. PubMedCrossRef
98.
Ali A, Mehmood A, Ali MU. Clinical profile of patients with biopsy proven lupus nephritis at a tertiary care hospital from Northern Pakistan, 1995 to 2012. J Pak Med Assoc. 2017;67:77–82. PubMed
99.
Nezhad ST, Sepaskhah R. Correlation of clinical and pathological findings in patients with lupus nephritis: a five-year experience in Iran. Saudi J Kidney Dis Transpl. 2008;19:32–40. PubMed
100.
Rong R, Wen Q, Wang Y, Zhou Q, Qiu Y, Lu M, Liu X, Chen W, Yu X. Prognostic significance of hypertension at the onset of lupus nephritis in Chinese patients: prevalence and clinical outcomes. J Hum Hypertens. 2022;36:153–62. PubMedCrossRef
101.
Moroni G, Vercelloni PG, Quaglini S, et al. Changing patterns in clinical-histological presentation and renal outcome over the last five decades in a cohort of 499 patients with lupus nephritis. Ann Rheum Dis. 2018;77:1318–25. PubMedCrossRef
102.
Henry N, Mellaza C, Fage N, et al. Retrospective and systematic analysis of causes and outcomes of thrombotic microangiopathies in routine clinical practice: an 11-year study. Front Med. 2021;8:566678. CrossRef
103.
Halimi J-M, Thoreau B, von Tokarski F, et al. What is the impact of blood pressure on neurological symptoms and the risk of ESKD in primary and secondary thrombotic microangiopathies based on clinical presentation: a retrospective study. BMC Nephrol. 2022;23:39. PubMedPubMedCentralCrossRef
104.
Dierkes F, Andriopoulos N, Sucker C, et al. Indicators of acute and persistent renal damage in adult thrombotic microangiopathy. PLoS ONE. 2012;7:e30886. PubMedPubMedCentralCrossRef
105.
Jamme M, Raimbourg Q, Chauveau D, et al. Predictive features of chronic kidney disease in atypical haemolytic uremic syndrome. PLoS ONE. 2017;12:e0177894. PubMedPubMedCentralCrossRef
106.
Rosado C, Bueno E, Felipe C, Valverde S, González-Sarmiento R. Study of the true clinical progression of autosomal dominant alport syndrome in a European population. Kidney Blood Press Res. 2015;40:435–42. PubMedCrossRef
107.
Dagher H, Buzza M, Colville D, Jones C, Powell H, Fassett R, Wilson D, Agar J, Savige J. A comparison of the clinical, histopathologic, and ultrastructural phenotypes in carriers of X-linked and autosomal recessive Alport’s syndrome. Am J Kidney Dis. 2001;38:1217–28. PubMedCrossRef
108.
Aksenova ME, Konkova NE, Tutelman KM. Blood pressure level and progression of renal disease in children with X-linked Alport syndrome. Nephrol. 2020;24:78–84.
Metadata
Title
Underlying Mechanisms and Treatment of Hypertension in Glomerular Diseases
Authors
Sahar H. Koubar
Alejandro Garcia-Rivera
Muner M. B. Mohamed
John E. Hall
Michael E. Hall
Mohamed Hassanein
Publication date
20-11-2023
Publisher
Springer US
Published in
Current Hypertension Reports
Print ISSN: 1522-6417
Electronic ISSN: 1534-3111
DOI
https://doi.org/10.1007/s11906-023-01287-9
Webinar | 08-11-2023 | 18:00 (CET)

Keynote Webinar | Spotlight on Diet and Diabetes

Watch now

An expert-led symposium exploring the prevention and management of type 2 diabetes through dietary interventions. Highlights include discussion of the recent EASD guidelines, therapeutic diets, food types and processing, plus psychological factors that influence patient success, and the drivers of healthy eating and diabetes control.
Prof. Mike Lean
Prof. Falko Sniehotta
Image Credits